Hottest Stocks (Over $10)	Hottest Stocks ($2-$10)	Biggest Losers (Over $10)	Biggest Losers ($2-$10)	Hottest Industries	Hottest Sectors	EPS / Sales Surprises
Enter Ticker Symbol:   Ticker Lookup Company Quote Company Profile Research Summary EPS Consensus Perspective Insider Transactions Price Performance

Enter any portion of the company’s name to find its corresponding ticker symbol:

Search for :

Zacks Company Profile for Repare Therapeutics Inc. (RPTX : NSDQ)

• Company Description    Repare Therapeutics Inc. is an oncology company. It utilizes genome-wide, CRISPR-enabled SNIPRx(R) platform to discover and develop targeted cancer therapies focused on genomic instability, including DNA damage repair. The Company's product pipeline includes RP-3500, which is in clinical stage. Repare Therapeutics Inc. is based in St-Laurent, Canada. Number of Employees: 129

• Price / Volume Information    Yesterday's Closing Price: $1.44 Daily Weekly Monthly 20 Day Moving Average: 67,871 shares Shares Outstanding: 42.89 (millions) Market Capitalization: $61.76 (millions) Beta: 0.84 52 Week High: $4.29 52 Week Low: $0.89 Short Interest Ratio:   % Price Change % Price Change Relative to S&P 500 4 Week -2.04% -6.39% 12 Week 60.00% 36.66% Year To Date 9.92% 2.96%

• Address & Contact Information Street Address Phone / Fax Email Address Web URL 7171 Frederick-Banting Building 2 Suite 270 - St-Laurent,A8 H4S 1Z9 CAN ph: 857-412-7018 fax: - investor@reparerx.com http://www.reparerx.com

• General Corporate Information    Officers Lloyd M. Segal - President and Chief Executive Officer Thomas Civik - Chairman Steve Forte - Executive Vice President; Chief Financial Officer David Bonita - Director Samarth Kulkarni - Director Peer Information Repare Therapeutics Inc. (CORR.) Repare Therapeutics Inc. (RSPI) Repare Therapeutics Inc. (CGXP) Repare Therapeutics Inc. (BGEN) Repare Therapeutics Inc. (GTBP) Repare Therapeutics Inc. (RGRX) Industry / Sector / Ticker Info Analyst Coverage: No Industry Group: MED-BIOMED/GENE Sector: Medical CUSIP: 760273102 SIC: 2834 Fiscal Year Fiscal Year End: December Last Reported Quarter: 03/01/25 Next Expected EPS Date: 08/05/25 Share - Related Items Shares Outstanding: 42.89 Most Recent Split Date: (:1) Beta: 0.84 Market Capitalization: $61.76 (millions)

• EPS Information     • Dividend Information Analyst Coverage: No Dividend Yield: 0.00% Current Fiscal Quarter EPS Consensus Estimate: $-0.49 Indicated Annual Dividend: $0.00 Current Fiscal Year EPS Consensus Estimate: $-2.45 Payout Ratio: Number of Estimates in the Fiscal Year Consensus: 2.00 Change In Payout Ratio: Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00 Next EPS Report Date: 08/05/25

• Fundamental Ratios P/E Current FY Estimate: - Trailing 12 Months: - PEG Ratio: - Price Ratios Price/Book: 0.49 Price/Cash Flow: - Price / Sales: 0.90 EPS Growth vs. Year Ago Period: -336.67% vs. Previous Quarter: -5.97% Sales Growth vs. Year Ago Period: -96.45% vs. Previous Quarter: -97.95% ROE 06/30/25 - - 03/31/25 - -78.12 12/31/24 - -44.47 ROA 06/30/25 - - 03/31/25 - -67.11 12/31/24 - -38.44 Current Ratio 06/30/25 - - 03/31/25 - 7.42 12/31/24 - 6.77 Quick Ratio 06/30/25 - - 03/31/25 - 7.42 12/31/24 - 6.77 Operating Margin 06/30/25 - - 03/31/25 - - 12/31/24 - - Net Margin 06/30/25 - - 03/31/25 - - 12/31/24 - - Pre-Tax Margin 06/30/25 - - 03/31/25 - -11,809.23 12/31/24 - -155.67 Book Value 06/30/25 - - 03/31/25 - 2.92 12/31/24 - 3.56 Inventory Turnover 06/30/25 - - 03/31/25 - - 12/31/24 - - Debt-to-Equity 06/30/25 - - 03/31/25 - 0.00 12/31/24 - 0.00 Debt-to-Capital 06/30/25 - - 03/31/25 - 0.00 12/31/24 - 0.00

Powered by Zacks Investment Research ©